@article{39e5d7e73a714e66b04de80ff188171c,
title = "Once-a-day administration of everolimus is safe in de novo renal transplant recipients: 1-year results of a pilot study",
abstract = "The half-life of everolimus is approximately 28 hours, but everolimus is generally administered twice a day. The aim of this prospective, single-center, exploratory study was to compare the efficacy and safety of a once a day everolimus (OD) with the standard twice a day administration regimen (BID) as immunosuppressive therapy in renal transplantation.",
keywords = "Administration, Oral, Antibodies, Monoclonal, Calcineurin, Chi-Square Distribution, Drug Administration Schedule, Drug Monitoring, Drug Therapy, Combination, Female, Graft Rejection, Graft Survival, Humans, Immunosuppressive Agents, Italy, Kidney Transplantation, Male, Pilot Projects, Prospective Studies, Recombinant Fusion Proteins, Risk Assessment, Risk Factors, Sirolimus, Time Factors, Treatment Outcome, Administration, Oral, Antibodies, Monoclonal, Calcineurin, Chi-Square Distribution, Drug Administration Schedule, Drug Monitoring, Drug Therapy, Combination, Female, Graft Rejection, Graft Survival, Humans, Immunosuppressive Agents, Italy, Kidney Transplantation, Male, Pilot Projects, Prospective Studies, Recombinant Fusion Proteins, Risk Assessment, Risk Factors, Sirolimus, Time Factors, Treatment Outcome",
author = "Franco Citterio and Gionata Spagnoletti and Salerno, {Maria Paola} and E Favi and A Gargiulo",
year = "2011",
doi = "10.1016/j.transproceed.2011.03.018",
language = "English",
volume = "43",
pages = "1010--1012",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier Science Incorporated / NY Journals:Madison Square Station, PO Box 882:New York, NY 10159:(212)633-3730, EMAIL: usinfo-f@elsevier.com, INTERNET: http://www.elsevier.com, Fax: (212)633-3680",
}